ETF - Go long on ULTRA NASDAQ BIOTECHNOLOGY ($BIB)ProShares Ultra Nasdaq Biotechnology seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Nasdaq Biotechnology Index®.
Key stats
About ProShares Ultra Nasdaq Biotechnology
Expense ratio
0.95%
Home page
Inception date
Apr 7, 2010
BIB, having been around since 2010, is a leveraged play on the NASDAQ Biotechnology Index (which is also tracked in unlevered form by iShares' IBB), and is heavily focused on NASDAQs biotechnology and pharmaceutical firms with a large-cap bias. The fund gains its 2x leveraged exposure to the index through several financial instruments (i.e. equity securities, derivatives and money-market instruments), and rebalances its exposure daily. Like all geared funds that rebalance daily, BIB is meant for short-term trading since compounding effects over the long-term could create vast differences from expected returnsfor good or for ill.
Classification
What's in the fund
Exposure type
Health Technology
Cash
Government
Stock breakdown by region
not worth buying nowWe into the retracement of buy ( long term ) cycle, which means a re-accumulation would happens before it starts moving upward seriously again. On the daily supply is still pretty heavy, which tells me more absorption of it have to happens and a spring ( move downward on steroid) is even a possibili
XBIoverlapped the ribbon to help with the visual. Embedded stoch and 9/20 mov avg pinch equates to more upside
NASDAQ AND S&P BIOTECH WITH HUGE BULLISH BREAKOUTSTextbook chart of an ending bottom and new uptrend starting. I don't want to miss out on this one, this could easily become the trade of the year.
The breakout is now confirmed, but i want to wait for a nice correction before entering.
S&P Biotech:
Blessings to you all.
See all ideas
Displays a symbol's price movements over previous years to identify recurring trends.